Evaluation of molnupiravir (EIDD-2801) efficacy against SARS-CoV-2 in the rhesus macaque model

Molnupiravir (EIDD-2801) is a prodrug of a ribonucleoside analogue that is currently being used under a US FDA emergency use authorization for the treatment of mild to moderate COVID-19. We evaluated molnupiravir for efficacy as an oral treatment in the rhesus macaque model of SARS-CoV-2 infection....

Descripción completa

Detalles Bibliográficos
Autores principales: Johnson, Dylan M., Brasel, Trevor, Massey, Shane, Garron, Tania, Grimes, Michael, Smith, Jeanon, Torres, Maricela, Wallace, Shannon, Villasante-Tezanos, Alejandro, Beasley, David W., Comer, Jason E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Authors. Published by Elsevier B.V. 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9756747/
https://www.ncbi.nlm.nih.gov/pubmed/36535309
http://dx.doi.org/10.1016/j.antiviral.2022.105492

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9756747/
https://www.ncbi.nlm.nih.gov/pubmed/36535309
http://dx.doi.org/10.1016/j.antiviral.2022.105492

Ejemplares similares